HIV Research Training Program

 描述（由申请人提供）：本申请是布法罗大学（UB）和津巴布韦大学（UZ）之间的艾滋病毒研究和培训计划（HRTP）。HRTP将建立在最近完成的艾滋病国际艾滋病毒研究和培训计划的基础上，该计划的重点是重新启动UZ艾滋病毒临床药理学研究硕士水平的研究生培训。艾滋病毒预防和治疗研究方面的科学突破已产生证据，表明涉及抢先体验抗逆转录病毒疗法的干预措施在预防艾滋病毒在怀孕、生育和分娩期间的性传播和垂直传播方面非常有效。津巴布韦的政府和学术界领导人已将艾滋病毒临床药理学研究确定为国家计划的关键组成部分，以获得抗逆转录病毒药物和艾滋病毒治疗，以实现这些科学突破。UB-UZ HRTP将专注于将临床药理学研究与以下方面相结合的新方面：1）抗逆转录病毒药物依从性，2）临床上重要的药代动力学药物相互作用（如抗结核药物、抗疟疾药物、激素避孕药和传统药物），3）妊娠期间抗逆转录病毒药物的处置（其次是世卫组织备选方案B+的实施）和婴儿，并确定子宫内抗逆转录病毒药物的接触情况，以及4）在广泛实施前对抗逆转录病毒药物仿制品进行生物等效性测试。这些研究领域与其他NIH资助的项目和区域能力建设相结合。HRTP将扩大培训重点，包括硕士，博士和博士后学员，并强调课程，为HRTP学员提供艾滋病毒临床药理学研究技能培训，以获得成为独立研究人员所需的技能。HRTP学员将在UB获得国际公认的HIV临床药理学实验室的重点临床药理学研究培训，该实验室补充了UZ临床药理学实验室计划。UB-UZ HRTP得到了UZ健康科学学院和卫生部的大力支持。HRTP将受益于一个专家培训咨询委员会和一批积极主动的教师，他们将提供课程，结构化的研究培训和项目评估，以确保高效，高效的艾滋病毒研究培训计划。

 DESCRIPTION (provided by applicant): This application is for a HIV Research and Training Program (HRTP) between the University at Buffalo (UB) and the University of Zimbabwe (UZ). The HRTP will build on a recently completed AIDS International HIV Research and Training Program that was focused on re-initiating postgraduate training at the Master's level in HIV clinical pharmacology research at UZ. Scientific breakthroughs in HIV prevention and treatment research have produced evidence suggesting that interventions involving early access to antiretroviral therapy (ART) are highly effective in preventing HIV sexual transmission and vertical transmission during pregnancy, childbearing and delivery. Government and academic leaders in Zimbabwe have identified HIV Clinical Pharmacology Research as a key component of national planning for ARV access and HIV therapeutics to implement these scientific breakthroughs. The UB-UZ HRTP will focus on novel aspects that integrate clinical pharmacology research with: 1) ARV adherence, 2) clinically important pharmacokinetic drug interactions (e.g. anti-tuberculosis drugs, anti- malarials, hormonal contraceptives and traditiona medicines), 3) ARV disposition during pregnancy (secondary to WHO Option B+ implementation) and in infants, and to determine in utero ARV exposure, and 4) bioequivalency testing for generic ARV products prior to widespread implementation. These research areas integrate well with other NIH funded projects and regional capacity building. The HRTP will broaden the training focus to include masters, doctoral and post-doctoral trainees and emphasize a curriculum that provides an HIV Clinical Pharmacology Research Skills Toolbox for HRTP trainees to gain the skillset that will be required to be an independent researcher. HRTP trainees will gain focused clinical pharmacology research training at UB in an internationally recognized HIV Clinical Pharmacology Laboratory that complements the UZ Clinical Pharmacology Laboratory program. The UB-UZ HRTP has strong support from the UZ College of Health Sciences and the Ministry of Health. The HRTP will benefit from an expert Training Advisory Committee and a complement of highly motivated faculty that will provide the curriculum, structured research training and program evaluation that will assure a highly productive, efficient HIV research training initiative.